## 1.1.2	Data used

### 1.1.2.1	In vitro / physchem data

A literature search was performed to collect available information on physical chemical properties of raltegravir. The obtained information from literature is summarized in the table below, and is used for model building.

| **Parameter**   | **Unit**    | **Raltegravir literature**                     | **Description**                |
| :-------------- | ----------- | ---------------------------------------------- | ------------------------------ |
| MW              | g/mol       | 586.2 ([drugbank.ca](../input/references.md))  | Molecular weight               |
| pKa             |             | 7.67 ([Moss 2012](../input/references.md))     | Acid dissociation constant     |
| Solubility (pH) | mg/L        | Reference pH-dependent table (Moss 2013)       | Solubility                     |
| logP            |             | 0.58 ([Moss 2012](../input/references.md))     | Lipophilicity                  |
| fu              |             | 0.17 ([Laufer 2009](../input/references.md))   | Fraction unbound               |
| UGT1A1          | µM          | 99 ([Kassahun 2007](../input/references.md))   | Michaelis-Menten constant (Km) |
| UGT1A1          | nmol/min/mg | 0.89 ([Kassahun 2007](../input/references.md)) | Vmax                           |
| UGT1A9          | µM          | 296 ([Kassahun 2007](../input/references.md))  | Michaelis-Menten constant (Km) |
| UGT1A9          | nmol/min/mg | 0.53 ([Kassahun 2007](../input/references.md)) | Vmax                           |

### 1.1.2.2	Clinical data

A literature search was performed to collect available clinical data on Raltegravir in adults. 

The following publications were found in adults for model building and evaluation:

Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, Merschman SA, Strohmaier KM, Ramael S, Lasseter KC, Stone JA, Gottesdiener KM, Wagner JA. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther. 2008 Feb;83(2):293-9. Epub 2007 Aug 22.

Iwamoto M, Wenning LA, Nguyen BY, Teppler H, Moreau AR, Rhodes RR, Hanley WD, Jin B, Harvey CM, Breidinger SA, Azrolan N, Farmer HF Jr, Isaacs RD, Chodakewitz JA, Stone JA, Wagner JA. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009 Feb 15;48(4):489-92. doi: 10.1086/596503.

Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):509-15.

Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner JA, Wenning LA. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007 Sep;35(9):1657-63. Epub 2007 Jun 25.

Rhee EG, Rizk ML, Brainard DM, Gendrano IN 3rd, Jin B, Wenning LA, Wagner JA, Iwamoto M. A pharmacokinetic comparison of adult and paediatric formulations of raltegravir in healthy adults. Antivir Ther. 2014;19(6):619-24. doi: 10.3851/IMP2765. Epub 2014 Mar 7.

Larissa A. Wenning,, William D. Hanley, Diana M. Brainard, Amelia S. Petry, Kalyan Ghosh, Bo Jin, Eric Mangin, Thomas C. Marbury, Jolene K. Berg, Jeffrey A. Chodakewitz, Julie A. Stone,1 Keith M. Gottesdiener, John A. Wagner, and Marian Iwamoto. Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir. Antimicrob Agents Chemother. 2009 Jul; 53(7): 2852–2856.

